Zaman’s onslaught helps Pak defeat Australia, win T20 tri-series title

Mumbai, Mar 6: Harried Yes Bank depositors rushed to ATMs to withdraw cash but faced multitude of problems including closed down machines and long queues, after the RBI placed the bank under a moratorium, capping maximum withdrawals at Rs 50,000 per account for a month.

Aggravating the problems of depositors were difficulties accessing the internet banking channel, which ensured that they can't transfer the funds online as well. At an ATM in south Mumbai's Horniman Circle, with the RBI headquarters overlooking it, the shutters were pulled down.

The guard on duty said the machine was non-operational before he reported to work late in the evening and he was ordered to shut it after 2200 hrs. In the residential area of suburban Chembur, one ATM was dispensing cash but had a long queue of anxious depositors.

One man said it was still possible to withdraw up to Rs 50,000 in multiple transactions from the machine.

However, another machine nearby had run dry within minutes of the RBI announcement, a woman said.

The regulatory actions, undertaken by the RBI and the government, came hours after finance ministry sources confirmed that SBI was directed to bail out the troubled lender.

For the next month, Yes Bank will be led by the RBI-appointed administrator Prashant Kumar, an ex-chief financial officer of SBI.

Jan 15: Australia openers David Warner and Aaron Finch both struck superb centuries to complement their bowlers’ inspired display as the touring side handed out a 10-wicket thrashing to India in the opening one-day international in Mumbai.

India, world-ranked No 2 in ODIs, suffered a middle-order collapse on their way to being bundled out for 255 in the final over of their innings after Australia captain Finch won the toss and opted to field in the first of the three-match series.

Warner and Finch then smashed the Indian bowlers to all corners of the ground, picking up boundaries seemingly at will to chase down the target with 74 balls to spare at the Wankhede Stadium.

Left-handed Warner successfully used the decision review system twice to overturn the umpire’s decision on his way to his 18th ODI century, hitting three sixes and 17 fours in his unbeaten knock of 128, from 112 balls. Finch completed his 16th century in the format, his unbeaten innings 110 from 114 features two sixes and 13 fours.

Earlier, Australia’s left-arm fast bowler Mitchell Starc, who made his ODI debut in India 10 years ago, picked up three wickets to set up Australia’s victory. He struck the first blow with the new ball when he sent back Rohit Sharma for 10.

India managed to recover from that early loss through a second-wicket stand of 121 between opener Shikhar Dhawan, who top-scored for the hosts with 74, and KL Rahul. However left-arm spinner Ashton Agar broke the stand by dismissing Rahul for 47 before Agar caught Dhawan off Pat Cummins in the next over.

The hosts were hoping for a solid innings from captain Virat Kohli, who batted a position lower than his usual No 3 spot to accommodate Rahul, to get them out of trouble. However, he lasted only 14 balls, hitting leg-spinner Adam Zampa for a six before offering a return catch to the bowler on the very next delivery to be out for 16.

Starc then returned to the attack, removing Shreyas Iyer cheaply as India lost four wickets for 30 runs to be reduced to 164 for five. Rishabh Pant and Ravindra Jadeja then fell just short of a half-century partnership, before the remaining four wickets falling for 42 runs, with Cummins and fast bowler Kane Richardson picking up two wickets apiece for Australia.

To compound India’s woes, wicketkeeper Pant suffered a concussion after being hit on his helmet by a short-pitched delivery from Cummins. The Indian cricket board said Pant, who did not come out to keep wicket and was replaced behind the stumps by Rahul, was under observation. The two sides will meet in Rajkot for the second ODI on Friday.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.